Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9UPQ8

UPID:
DOLK_HUMAN

ALTERNATIVE NAMES:
Transmembrane protein 15

ALTERNATIVE UPACC:
Q9UPQ8; Q5SRE6

BACKGROUND:
Dolichol kinase catalyzes the final step in the de novo synthesis of dolichyl monophosphate, a key lipid carrier for glycosylation processes. This enzyme's function underscores its importance in the production of glycoproteins, which are vital for embryonic development and cell maintenance.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Dolichol kinase could open doors to potential therapeutic strategies for addressing Congenital disorder of glycosylation 1M. By elucidating the enzyme's role in glycoprotein biosynthesis, researchers can pave the way for innovative treatments for this and related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.